Allergan to cash in on eyelash stimulant effect of glaucoma drug

June 13, 2008

Article

Following positive clinical trial results, Allergan, the makers of bimatoprost, are submitting a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking a new indication for the prostaglandin analogue as an eyelash growth stimulant.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos

Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times

SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium

Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.

Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe

Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe

Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)

Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium

At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients

$At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery$

Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.

Related Content

AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease

Abigail Lewis, editorial intern

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD

A very young child sits in a car seat while an adult smokes a cigarette near them. Concept image for secondhand smoke, exposure to smoking and early onset myopia development and progression in children. Image credit: ©New Africa – stock.adobe.com

Secondhand smoke is environmental risk factor in myopia development, study suggests

The researchers shared the first cohort study established in China that examines the relationship between secondhand smoke and early onset of myopia

A row of beakers with yellow and orange fluid in a laboratory. Concept image for microbial lutein production, bioengineering, sustainable synthesis for cataract cornea age-related macular degeneration (AMD) and retinal disease. Image credit: bidala – stock.adobe.com

New microbial strain produces high yields of lutein for AMD, cataract prevention

Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Related Content

AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease

Abigail Lewis, editorial intern

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD

A very young child sits in a car seat while an adult smokes a cigarette near them. Concept image for secondhand smoke, exposure to smoking and early onset myopia development and progression in children. Image credit: ©New Africa – stock.adobe.com

Secondhand smoke is environmental risk factor in myopia development, study suggests

The researchers shared the first cohort study established in China that examines the relationship between secondhand smoke and early onset of myopia

A row of beakers with yellow and orange fluid in a laboratory. Concept image for microbial lutein production, bioengineering, sustainable synthesis for cataract cornea age-related macular degeneration (AMD) and retinal disease. Image credit: bidala – stock.adobe.com

New microbial strain produces high yields of lutein for AMD, cataract prevention

Researchers at the Korea Advanced Institute of Science and Technology demonstrated the next-generation strategy for sustainable synthesis

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Study data link cannabis use to lower risk of proliferative vitreoretinopathy after retinal detachment repair

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients

Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

Editorial Board

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.